"Medical quick reading society" East a glue changes commander! 2019 performance pressure

[January 20, 2020 / list of medical information] four major distributors are responsible for distribution in Shanghai; Xinda biological class 1 innovative drug ibi322 is approved for clinical application; Sichuan is the first one to imitate and approve the drug "dutahostamine soft capsule"; verrica's candidate new drug phase III is expected to become the first treatment drug for Infectious Soft warts Daily fresh medicine news, speed reading club and you pay attention to! After the announcement of the results of the second batch of national drug centralized purchase, Shanghai took the lead in publicizing the distribution enterprises in the region Among them, there are 16 selected varieties distributed by Shanghai Pharmaceutical Holding Co., Ltd., 10 selected varieties distributed by China Pharmaceutical Holding Co., Ltd., and 3 selected varieties distributed by Shanghai Sifu Pharmaceutical Co., Ltd (cypress blue) On August 18, the National Conference on drug registration management and post marketing supervision in 2020 was concluded in Beijing This conference is the National Conference on drug registration management and post marketing Supervision held after the implementation of the new drug management law, which deployed the key work of national drug registration management and post marketing supervision in 2020 (CPHI Pharma online) On the 19th, dong'a Ejiao announced that it had recently received a written resignation report from Mr Qin Yufeng At the same time, upon the nomination of the controlling shareholders, dong'a-jiao agreed that Mr Gao Dengfeng would be the candidate for the ninth board of directors of the company, with the tenure consistent with that of the ninth board of directors of the company (Medical Geography) Yidixi completed round a financing of tens of millions of RMB in early 2020 This round is invested exclusively by Qiming venture capital, which fully supports the development, team optimization and market expansion of yidixi clinflash series clinical trial system (arterial network) On the 20th, AstraZeneca and mosadon announced that lynparza's application for new drugs has been accepted in the United States and has been granted the priority qualification for examination It is used for patients with metastatic castration resistant prostate cancer, carrying harmful or suspected harmful germline or homologous recombination repair gene mutation These patients have disease progress after receiving the treatment of new hormone drugs in the past (yaomingkant) On September 19, CDE announced a new batch of applications to be included in the priority review and approval list, including the listing application of the sustained-release tablet of euripidone It is reported that the sustained-release tablet of palipexone, developed by Xi'an Janssen, was approved by the US FDA in 2006 for the treatment of schizophrenia It is the first prescription drug approved by the FDA for the treatment of schizophrenia since 2003 (Sina Medical News) On July 17, Watson biology announced that its subsidiary, Shanghai Zerun, independently developed the clinical research of recombinant human papillomavirus bivalent (16 / 18) vaccine, completed the phase III clinical trial data Unblinding work and entered the stage of statistical analysis and clinical research summary of clinical trial data (medicine cube) Sichuan Guowei Pharmaceutical Co., Ltd has obtained the approval of the State Food and Drug Administration for listing of the dutasteride soft capsule declared in accordance with the new 4 categories, which is deemed to have passed the consistency evaluation It is reported that dutasteride is a 5 α - reductase inhibitor developed by GSK, which is used to treat the moderate and severe symptoms of BPH (medicine cube) On September 19, the CDE clinical tacit license column updated data, in which the class 1 innovative drug ibi322 of Cinda biology was approved for clinical use, with indications of solid tumors and blood tumors Ibi-322 is an anti-CD47 / PD-L1 bispecific antibody, which inhibits the binding of CD47 to SIRP α and the binding of PD-L1 to PD-1 (Insight database) Recently, verrica company released a positive data of vp-102 treatment of Infectious Soft warts in the critical phase III camp trial The results showed that in all body parts, the percentage of patients in the vp-102 treatment group who experienced complete removal of lesions was significantly higher than that in the excipient group (Sina Medical News) Chuangsheng group today announced that the clinical trial application of claudin 18.2 humanized monoclonal antibody submitted by its Suzhou subsidiary, mabos bio, to the drug review center of the State Drug Administration has been accepted by nmpa It is reported that tst001 is the first project jointly developed by both teams since the merger of Chuangsheng group It takes less than 12 months from the determination of candidate drugs to the application of clinical trials (American news agency) Recently, intercept pharmaceuticals announced that the U.S FDA has postponed the review and decision date of its potential first Nash new drug, obacholic acid For NASH, which has not yet come out of innovative therapy, it is a good thing (yaomingkant) Recently, the U.S FDA advisory committee discussed the listing application of posimir, a non opioid postoperative analgesic developed by durect, and the voting result was 6:6 The FDA advisory committee has yet to reach a consensus on the approval of the non opioid painkiller (yaomingkant)